ProtOS
- Biotech or pharma, therapeutic R&D
ProtOS is an AI-first protein design company developing therapeutics to target undruggables. Our AI foundation models create therapeutic proteins that enable a paradigm shift in drug development - from accidental discovery to intentional design.
ProtOS’ TPD platform offers unique target specificity and degradation efficiency, particularly for challenging unstructured targets and SNPs, applicable in oncology and neurodegenerative disease.
ProtOS seeks a discovery-stage partnership ($50–300K) to (a) co-select 1–2 prioritized undruggable targets; and (b) co-develop and validate bespoke degraders in joint assays.
ProtOS is backed by the discoverer of the ubiquitin mechanism, Nobel Laureate Prof. Aaron Ciechanover, and TPD pioneer Prof. Allesio Ciulli.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}